Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acrivon Therapeutics, Inc. - Common Stock (NQ: ACRV )

7.290 -0.040 (-0.55%)
Streaming Delayed Price Updated: 10:41 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,462
Open 7.300
Bid (Size) 7.190 (4)
Ask (Size) 7.280 (1)
Prev. Close 7.330
Today's Range 7.240 - 7.390
52wk Range 3.190 - 13.20
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024
ACRV stock results show that Acrivon Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+45.51%
+45.51%
1 Month
+10.29%
+10.29%
3 Month
-23.34%
-23.34%
6 Month
+62.72%
+62.72%
1 Year
-41.02%
-41.02%

More News

Read More
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Acrivon Therapeutics: Q4 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Crude Oil Down Over 1%; Cognyte Software Shares Plummet
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Dips 150 Points; Laser Photonics Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Is Rail Vision (RVSN) Stock Up 17% Today?
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost
Via InvestorPlace
Acrivon Therapeutics Stock Is Soaring Tuesday: What's Going On?
Via Benzinga
Dow Gains Over 50 Points; Neogen Posts Downbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Acrivon Therapeutics Announces $130 Million Private Placement Financing
From Acrivon Therapeutics, Inc
Via GlobeNewswire
ACRV Stock Earnings: Acrivon Therapeutics Misses EPS for Q4 2023
Via InvestorPlace
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.